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Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious dis-
eases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The 
mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to 
improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials. 
Among the observational studies, CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other 
Enterobacteriaceae) has contributed seminal multicenter data describing risk factors and clinical outcomes of carbapenem-resistant 
Enterobacteriaceae (CRE) in sentinel US hospitals. Building on this success, CRACKLE II will expand the network to hospitals 
across the United States and Colombia. Similar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas 
aeruginosa (SNAP and POP studies). In addition, the CREST study (Carbapenem-Resistant Enterobacteriaceae in Solid Organ 
Transplant Patients) has provided pivotal data on extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae and CRE 
carriage among solid organ transplant recipients to inform management of this vulnerable patient population. Two clinical trials to 
define novel ways of using an existing antibiotic, fosfomycin, to treat ESBL-producing Enterobacteriaceae (one that has completed 
enrollment and the other in late protocol development) will determine the clinical efficacy of fosfomycin as step-down oral therapy 
to treat complicated urinary tract infections. Additional clinical studies and trials using immunotherapeutic or newly approved 
agents are also in the planning stage, with the main goals of generating actionable data that will inform clinical decision making and 
facilitate development of new treatment options for highly resistant gram-negative bacterial infections.
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Antimicrobial resistance in gram-negative bacterial path-
ogens has reached a critical level where treatment options 
have become extremely limited for some types of infections 
[1, 2]. Resistance of Escherichia coli to oral agents such as 
trimethoprim-sulfamethoxazole and fluoroquinolones has 
eroded the utility of these antibiotics, leaving few options 
for the treatment of urinary tract infections in healthcare 
and community settings. Furthermore, cephalosporin resist-
ance due to production of extended-spectrum β-lactamase 
(ESBL) has become commonplace in E.  coli [3]. Resistance 
to carbapenems, once reliable and safe options for the treat-
ment of serious gram-negative infections caused by drug-re-
sistant organisms, has increased in the last decade among 
healthcare-associated pathogens, including Pseudomonas 
aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, 
and other carbapenem-resistant Enterobacteriaceae (CRE). 
Systemic infections from these organisms carry unacceptably 
high mortality, as high as 50%, because of the lack of effica-
cious treatment regimens [4].
Antimicrobial resistance in gram-negative pathogens has 
implications beyond the immediate issues of morbidity and 
mortality. None of the advances of modern medicine such as 
complex surgery, transplantation, cancer chemotherapy, and 
intensive care are possible without reliable means to treat the 
infections that inevitably complicate them.
The Antibacterial Resistance Leadership Group (ARLG) 
provides a framework to prioritize and implement clini-
cal studies to advance knowledge of the most challenging 
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antimicrobial resistance problems and improve the clinical out-
come of patients affected by antimicrobial-resistant infections. 
The long-term goals of the ARLG Gram-Negative Committee 
are to identify, design, and implement transformational clinical 
trials to improve outcomes of extensively drug-resistant (XDR) 
gram-negative infections and to minimize opportunities for 
further resistance to occur. Here, we review the ARLG’s activi-
ties in the field of gram-negative infections over its first 3 years 




Carbapenem resistance, increasingly common in K.  pneumo-
niae, represents a major threat to our population. Since the first 
carbapenem-resistant K. pneumoniae (CRKP) strain producing 
K.  pneumoniae carbapenemase (KPC) was identified in 1996, 
the incidence of infections due to CRKP has increased dramati-
cally [4]. The rise in resistance to colistin and tigecycline, agents 
of last resort with activity against CRKP, is particularly concern-
ing [16].
Despite the rapid spread of CRKP in the United States, the 
epidemiology, clinical impact, and longer-term outcomes of 
patients colonized or infected with CRKP remained unclear. 
To address this knowledge gap, CRACKLE (Consortium 
on Resistance Against Carbapenems in Klebsiella pneumo-
niae and Other Enterobacteriaceae) was launched in 2011 as 
a multicenter observational cohort of hospitalized patients 
infected or colonized with CRKP [17]. With the initial sup-
port of the Clinical and Translational Science Collaborative 
(UL1TR000439), 3 major healthcare systems in the Cleveland 
area began working together to gather clinical data and CRKP 
isolates from hospitalized patients in a standardized and pro-
spective manner [5]. With support from the ARLG, 10 addi-
tional sites were added and enrollment was expanded to include 
all CRE. To date, more than 1100 admissions from over 800 
patients have been included in the study. The key findings of 
CRACKLE that have been reported to date are summarized in 
Table 2 [2, 4–11]. Building on this success, a nationwide expan-
sion is in process that will include 32 study sites throughout 
the continental United States and Colombia (CRACKLE II; 
Figure 1). Collaborations with the ARLG Laboratory Center 
[18], Statistical and Data Management Center (SDMC) [19], 
Table 1. Antibacterial Resistance Leadership Group Studies Addressing Unmet Needs in Gram-Negative Bacterial Infections
Study Title/Topic Description Status
Observational
 CRACKLE I Consortium on Resistance Against Carbapenems in 
Klebsiella pneumoniae and Other Enterobacteriaceae I
Natural history of CRE infection/colonization Completed  [5–11]
 CRACKLE II Natural history of CRE infection/colonization; 
expanded to include all census regions
Ongoing
 ESBL Bacteremia Clinical outcome of ESBL bacteremia Empiric therapy; clinical decision tree Completed [12, 13]
 CREST Carbapenem-Resistant Enterobacteriaceae in Solid Organ 
Transplant Patients
Active surveillance of solid organ transplant patients 
to determine the impact of ESBL-E/ 
CRE carriage on outcome
Completed
 SNAP Study Network of Acinetobacter as an XDR Pathogen Natural history of XDR Acinetobacter infection/ 
colonization
Planning stage
 POP Pseudomonas and Other Lactose-Non-Fermenting 
Pathogens
Natural history of MDR Pseudomonas infection/ 
colonization
Planning stage
 PRIMERS Platforms for Rapid Identification of MDR Gram-Negative 
Bacteria and Evaluation of Resistance Studies




 PROOF Pharmacokinetics, Pharmacodynamics and Safety/ 
Tolerability of Two Dosing Regimens of Oral Fosfomycin 
Tromethamine in Healthy Adult Participants
PK/PD and safety/tolerability of 2 oral fosfomycin 
regimens in healthy adults
Ongoing
 FOCUS Phase IV Randomized, Double-Blind Trial to Evaluate the 
Efficacy of Fosfomycin Oral Versus Levofloxacin in 
Complicated Urinary Syndromes
Randomized, placebo-controlled, active control 
study of oral fosfomycin as a step-down therapy 
for cUTI
Planning stage
 ACUMIN Acute Care Unit Minocycline PK/PD of intravenous minocycline among critically 
ill adults
Planning stage
 PK2 Pharmacokinetics of Plazomicin in Kids PK/PD of plazomicin in adolescents, children, and 
infants
Planning stage
 PROPEL Pharmacokinetics of Plazomicin in the Epithelial Lining ELF penetration of plazomicin in patients with VAP/
HAP
Planning stage
 GC MASTERMIND Gonorrhea and Chlamydia Master Protocol for Diagnostics Evaluate diagnostics for extragenital gonorrhea and 
chlamydia
Ongoing
Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; cUTI, complicated urinary tract infection; ELF, epithelial lining fluid; ESBL-E, extended-spectrum β-lactamase–producing 
Enterobacteriaceae; HAP, hospital-acquired pneumonia; MDR, multidrug-resistant; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, pharmacokinetic; VAP, ventilator-as-
sociated pneumonia; XDR, extensively drug-resistant.
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and Leadership and Operations Center (LOC) [20] have also 
enabled expansion of database, operational, and laboratory 
and statistical analysis capabilities in CRACKLE II, including 
exploring direct electronic health record feeds. This follow-up 
study is specifically aimed at informing the designs of interven-
tional diagnostic and therapeutic trials addressing CRE infec-
tions. The first patient was enrolled in CRACKLE II in July 2016.
ESBL-producing bacteria are a major driver of carbapenem 
use and are increasing in prevalence; yet the optimal empiric 
therapy for bacteremia caused by these organisms is not defined. 
With support from the ARLG, 2 studies have been conducted 
to address this question. In a large cohort of patients with ESBL 
bacteremia, comparison of empiric therapy with carbapenems 
and piperacillin-tazobactam showed that the former was asso-
ciated with improved survival after adjustments [12]. Using the 
underlying cohort of bacteremia patients, a clinical decision tree 
was generated that has high positive and negative predictive val-
ues for ESBL bacteremia [13]. These findings should facilitate 
institution of early optimal therapy for this challenging infection.
Solid organ transplant (SOT) patients constitute a special pop-
ulation that is vulnerable to ESBL-producing Enterobacteriaceae 
(ESBL-E) and CRE infection. Due to their profoundly immu-
nocompromised status, outcomes of SOT patients who develop 
CRE infection remain suboptimal [21]. However, the natural 
history of ESBL-E/CRE colonization and subsequent infection 
after SOT remains unclear. CREST (Carbapenem-Resistant 
Enterobacteriaceae in Solid Organ Transplant Patients) is a 
longitudinal cohort study to better define risk of colonization 
and infection (lung, liver, and small bowel) in these patients. 
Enrollment is complete for CREST, and the full findings will be 
reported soon.
XDR Acinetobacter and Pseudomonas
Building upon the success of CRACKLE, similar natural 
history studies are in the planning stage for A.  baumannii 
(Study Network of Acinetobacter as XDR Pathogen [SNAP]) 
and P.  aeruginosa (Pseudomonas and Other Lactose-Non-
Fermenting Pathogens [POP]). Acinetobacter baumannii and 
P.  aeruginosa are highly problematic XDR pathogens, and 
treatment options are even more limited than for CRE. The 
goals of SNAP and POP are to elucidate the epidemiology, clin-
ical presentation, and outcome of all XDR A. baumannii and 
P. aeruginosa infection/colonization cases at network hospitals, 
and to determine the molecular epidemiology of the isolates. 
These data will inform the design of future treatment trials.
INTERVENTIONAL STUDIES
Oral Step-down Therapy for Urinary Tract Infections
Oral treatment options of urinary tract infections (UTIs) are 
increasingly limited due to worsening antimicrobial resistance 
among E. coli strains in the community. Oral agents that used 
to be first-line for the treatment of upper UTI (pyelonephritis) 
and lower UTI (cystitis), such as trimethoprim-sulfamethoxa-
zole and fluoroquinolones, are no longer consistently reliable 
due to high resistance rates [22].
Table 2. Key Findings From CRACKLE
Finding
• Severe acute illness (median Pitt bacteremia score [2]) and underlying chronic comorbidities (median Charlson score [4]) were common in patients infected 
and/or colonized with CRE [5]
• Hospitalizations during which CRE are isolated tended to be prolonged (median length of stay, 9 days) and included an ICU stay in 51% of patients [5]
• Overall mortality = 18%
 ° Associated mortality highest in patients with CRE pneumonia (hospital mortality, 34%; aHRa, 3.44) and bacteremia (hospital mortality, 38%; aHRa, 2.59)
 ° No additional mortality was observed in patients with CRE UTI [5, 6]
• Readmissions during which CRE were again isolated occurred in 20% of patients within 90 days of discharge [7]
• Tigecycline use may lead to sequential tigecycline resistance, and stay in long-term care facilities was found to be a risk factor [8, 9]
• Common CRKP strain types included ST258A and ST258B [5, 10, 11]
• ST258A was associated with higher treatment failure rates in CRKP bacteriuria [10]
• Aminoglycoside was associated with improved outcomes and tigecycline was associated with worse outcomes in patients treated for CRKP bacteriuria [10]
Abbreviations: aHR adjusted hazard ratio; CRACKLE, Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobacteriaceae; CRE, carbapenem-resistant 
Enterobacteriaceae; CRKP, carbapenem-resistant Klebsiella pneumoniae; ICU, intensive care unit; UTI, urinary tract infection.
aCRE urinary colonization was used as the reference group.
Figure  1. Locations of planned US study sites for CRACKLE II (Consortium 
on Resistance Against Carbapenems in Klebsiella pneumoniae and Other 
Enterobacteriaceae).
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Fosfomycin is an old agent that remains active against 
most E.  coli strains and can be taken orally [23]. In the 
United States, however, it is currently only approved for a 
single-dose treatment of uncomplicated lower UTI. Two 
sequential studies are being implemented and planned, 
respectively, to test efficacy of fosfomycin as a multiple-dose 
oral step-down for complicated UTIs. The first, a collabora-
tion with the Pharmacokinetics Special Emphasis Panel and 
the ARLG SDMC and LOC, is PROOF (Pharmacokinetics, 
Pharmacodynamics and Safety/Tolerability of Two Dosing 
Regimens of Oral Fosfomycin Tromethamine in Healthy 
Adult Participants) to identify the optimal dosing sched-
ule of oral fosfomycin to be tested for the treatment of 
pyelonephritis and complicated UTI. PROOF has enrolled 
healthy subjects who receive daily or every-other-day dos-
ing of fosfomycin tromethamine 3  g by mouth in a ran-
domized crossover study. One of these 2 regimens will be 
selected for FOCUS (Phase IV Randomized, Double-Blind 
Trial to Evaluate the Efficacy of Fosfomycin Oral Versus 
Levofloxacin in Complicated Urinary Syndromes), based on 
the steady-state pharmacokinetics and pharmacodynamics 
data obtained through PROOF. FOCUS will test whether 
fosfomycin tromethamine is as efficacious as levofloxa-
cin as oral step-down therapy in treating complicated UTI, 
including pyelonephritis. Up to 3  days of prestudy therapy 
(expected to be mostly intravenous therapy in-hospital) will 
be allowed, followed by 5–7  days of study medication—a 
step-down study design that reflects clinical practice.
MINOCYCLINE PHARMACOKINETICS IN CRITICALLY 
ILL PATIENTS
Acinetobacter baumannii is a healthcare-associated pathogen 
characterized by its propensity for extensive drug resistance. 
Especially problematic is carbapenem-resistant A. baumannii, 
an important cause of pneumonia, bacteremia, and wound 
infection among critically ill patients for which very few treat-
ment options are available [24]. A new intravenous formulation 
of minocycline made available in 2015 is approved by the US 
Food and Drug Administration for the treatment of infections 
due to Acinetobacter species, is active against the majority of 
XDR A.  baumannii strains, and is well tolerated, making it a 
potential treatment option for XDR A.  baumannii infections. 
However, the pharmacokinetic characteristics of minocycline 
in the critically ill are unknown. ACUMIN (Acute Care Unit 
Minocycline), another collaboration with the Pharmacokinetics 
Special Emphasis Panel, is a pharmacokinetic study designed to 
address this knowledge gap. ACUMIN will develop a popula-
tion pharmacokinetic model for minocycline following a single 
200-mg intravenous infusion over 60 minutes in up to 50 crit-
ically ill patients. The results of ACUMIN will inform optimal 
dosing of minocycline in the critically ill patient population 
most likely to receive this agent.
PLAZOMICIN PHARMACOKINETICS IN CHILDREN 
AND CRITICALLY ILL PATIENTS
Plazomicin is a novel aminoglycoside currently in phase 3 
clinical development for the treatment of complicated UTIs, 
including acute pyelonephritis and serious infections caused 
by CRE. Plazomicin has activity against most CRE strains, 
including strains that are resistant to currently available amino-
glycosides, and is active against KPC-producing K.  pneumo-
niae, which accounts for most CRE identified in the United 
States [25]. Continuing the strong collaboration with the 
Pharmacokinetics Special Emphasis Panel, 2 pharmacokinetic 
studies are in the planning stage to inform dosing of plazomicin 
once it is approved for clinical use. PK2 (Pharmacokinetics of 
Plazomicin in Kids) is a phase 1, open-label study to evaluate 
the pharmacokinetics of plazomicin in adolescents, children, 
and infants that will provide pivotal data supporting pediat-
ric dosing of plazomicin from preterm infants to adolescents. 
PROPEL (Pharmacokinetics of Plazomicin in the Epithelial 
Lining) is a phase 1, prospective, multicenter, randomized study 
to evaluate the epithelial lining fluid penetration of plazomicin 
in patients with nosocomial pneumonia. Importantly, PROPEL 
will address lung penetration of plazomicin in the actual patient 
population likely to need this agent once approved, an impor-
tant consideration for novel antibacterial agents.
UNMET NEEDS AND OPPORTUNITIES
Resistance of gram-negatives is at the forefront of the cur-
rent crisis of antibiotic resistance with major challenges in 
prevention, diagnosis, and treatment of infections caused by 
these organisms. A  key mission of the ARLG Gram-Negative 
Committee is to advance knowledge of gram-negative bacterial 
infections, especially those with XDR pathogens, and conduct 
studies to test novel diagnostic and treatment options that will 
improve clinical care and patient outcome. Currently, the prior-
ity XDR pathogens include CRE, A. baumannii, and P. aerugi-
nosa. Several new treatment options are becoming available for 
CRE, but options for other organisms continue to be extremely 
limited and will be the focus in coming years.
Numerous challenges in conducting clinical trials addressing 
infections from XDR pathogens include difficulty in identify-
ing and enrolling patients in the target population, changes in 
epidemiology, delay in diagnosis, concomitant or polymicrobial 
infection, and baseline illness (Table 3). A deeper understanding 
of the natural history of these infections is essential for design-
ing and implementing feasible clinical trials. CRACKLE II is 
designed specifically to collect typical inclusion and exclusion 
criteria of interventional trials and document the outcome of 
CRE infections to allow for early assessment of trial feasibility. 
Similar natural history studies are being conceived for A. bau-
mannii and P. aeruginosa. These studies provide an opportunity 
to significantly facilitate design and conduct of randomized 
clinical trials.
S34 • CID 2017:64 (Suppl 1) • Doi et al
An emerging opportunity is the role of ARLG in public–
private partnerships. Several studies taking advantage of such 
partnerships are in the planning stages and more are under con-
sideration for the treatment of gram-negative infections. These 
partnerships provide platforms to synergize the expertise and 
resources to conduct studies that may not be conducted other-
wise to inform clinical practice. Whereas preclinical and early 
clinical studies for new treatments have in the past been almost 
exclusively conducted in the private sector, we anticipate that 
the combined expertise and resources of the public, private, and 
academic sectors will establish new paradigms to advance the 
field and facilitate antibiotic drug development.
CONCLUSIONS
The ARLG has implemented and is planning multiple studies 
addressing unmet needs posed by gram-negative pathogens 
and infections. These include natural history studies, pharma-
cokinetic and pharmacodynamic studies, and interventional 
trials, each designed to address gaps in knowledge. The ARLG 
continues to prioritize observational and interventional studies 
in the field of gram-negative resistance, with the goal of gener-
ating information that will directly and positively impact man-
agement of patients with infections caused by these organisms.
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